These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 36717539)

  • 21. Casirivimab and Imdevimab for the Treatment of Hospitalized Patients With COVID-19.
    Somersan-Karakaya S; Mylonakis E; Menon VP; Wells JC; Ali S; Sivapalasingam S; Sun Y; Bhore R; Mei J; Miller J; Cupelli L; Forleo-Neto E; Hooper AT; Hamilton JD; Pan C; Pham V; Zhao Y; Hosain R; Mahmood A; Davis JD; Turner KC; Kim Y; Cook A; Kowal B; Soo Y; DiCioccio AT; Geba GP; Stahl N; Lipsich L; Braunstein N; Herman GA; Yancopoulos GD; Weinreich DM;
    J Infect Dis; 2022 Dec; 227(1):23-34. PubMed ID: 35895508
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ivermectin to prevent hospitalizations in patients with COVID-19 (IVERCOR-COVID19): a structured summary of a study protocol for a randomized controlled trial.
    Vallejos J; Zoni R; Bangher M; Villamandos S; Bobadilla A; Plano F; Campias C; Chaparro Campias E; Achinelli F; Guglielmone HA; Ojeda J; Medina F; Farizano Salazar D; Andino G; Ruiz Diaz NE; Kawerin P; Meza E; Dellamea S; Aquino A; Flores V; Martemucci CN; Vernengo MM; Martinez SM; Segovia JE; Aguirre MG
    Trials; 2020 Nov; 21(1):965. PubMed ID: 33234158
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety and immunogenicity of a live-attenuated influenza virus vector-based intranasal SARS-CoV-2 vaccine in adults: randomised, double-blind, placebo-controlled, phase 1 and 2 trials.
    Zhu F; Zhuang C; Chu K; Zhang L; Zhao H; Huang S; Su Y; Lin H; Yang C; Jiang H; Zang X; Liu D; Pan H; Hu Y; Liu X; Chen Q; Song Q; Quan J; Huang Z; Zhong G; Chen J; Han J; Sun H; Cui L; Li J; Chen Y; Zhang T; Ye X; Li C; Wu T; Zhang J; Xia NS
    Lancet Respir Med; 2022 Aug; 10(8):749-760. PubMed ID: 35644168
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial.
    Wang Y; Zhang D; Du G; Du R; Zhao J; Jin Y; Fu S; Gao L; Cheng Z; Lu Q; Hu Y; Luo G; Wang K; Lu Y; Li H; Wang S; Ruan S; Yang C; Mei C; Wang Y; Ding D; Wu F; Tang X; Ye X; Ye Y; Liu B; Yang J; Yin W; Wang A; Fan G; Zhou F; Liu Z; Gu X; Xu J; Shang L; Zhang Y; Cao L; Guo T; Wan Y; Qin H; Jiang Y; Jaki T; Hayden FG; Horby PW; Cao B; Wang C
    Lancet; 2020 May; 395(10236):1569-1578. PubMed ID: 32423584
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Astegolimab or Efmarodocokin Alfa in Patients With Severe COVID-19 Pneumonia: A Randomized, Phase 2 Trial.
    Waters M; McKinnell JA; Kalil AC; Martin GS; Buchman TG; Theess W; Yang X; Lekkerkerker AN; Staton T; Rosenberger CM; Pappu R; Wang Y; Zhang W; Brooks L; Cheung D; Galanter J; Chen H; Mohan D; Peck MC;
    Crit Care Med; 2023 Jan; 51(1):103-116. PubMed ID: 36519984
    [TBL] [Abstract][Full Text] [Related]  

  • 26. PCSK9 Inhibition During the Inflammatory Stage of SARS-CoV-2 Infection.
    Navarese EP; Podhajski P; Gurbel PA; Grzelakowska K; Ruscio E; Tantry U; Magielski P; Kubica A; Niezgoda P; Adamski P; Junik R; Przybylski G; Pilaczyńska-Cemel M; Rupji M; Specchia G; Pinkas J; Gajda R; Gorog DA; Andreotti F; Kubica J
    J Am Coll Cardiol; 2023 Jan; 81(3):224-234. PubMed ID: 36653090
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of Bamlanivimab vs Placebo on Incidence of COVID-19 Among Residents and Staff of Skilled Nursing and Assisted Living Facilities: A Randomized Clinical Trial.
    Cohen MS; Nirula A; Mulligan MJ; Novak RM; Marovich M; Yen C; Stemer A; Mayer SM; Wohl D; Brengle B; Montague BT; Frank I; McCulloh RJ; Fichtenbaum CJ; Lipson B; Gabra N; Ramirez JA; Thai C; Chege W; Gomez Lorenzo MM; Sista N; Farrior J; Clement ME; Brown ER; Custer KL; Van Naarden J; Adams AC; Schade AE; Dabora MC; Knorr J; Price KL; Sabo J; Tuttle JL; Klekotka P; Shen L; Skovronsky DM;
    JAMA; 2021 Jul; 326(1):46-55. PubMed ID: 34081073
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and safety of nelfinavir in asymptomatic and mild COVID-19 patients: a structured summary of a study protocol for a multicenter, randomized controlled trial.
    Hosogaya N; Miyazaki T; Fukushige Y; Takemori S; Morimoto S; Yamamoto H; Hori M; Kurokawa T; Kawasaki Y; Hanawa M; Fujii Y; Hanaoka H; Iwami S; Watashi K; Yamagoe S; Miyazaki Y; Wakita T; Izumikawa K; Yanagihara K; Mukae H; Kohno S;
    Trials; 2021 Apr; 22(1):309. PubMed ID: 33910617
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A phase 2 randomized, double-blinded, placebo-controlled, multicenter trial evaluating the efficacy and safety of raloxifene for patients with mild to moderate COVID-19.
    Nicastri E; Marinangeli F; Pivetta E; Torri E; Reggiani F; Fiorentino G; Scorzolini L; Vettori S; Marsiglia C; Gavioli EM; Beccari AR; Terpolilli G; De Pizzol M; Goisis G; Mantelli F; Vaia F; Allegretti M;
    EClinicalMedicine; 2022 Jun; 48():101450. PubMed ID: 35582123
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of anti-interleukin drugs in patients with COVID-19 and signs of cytokine release syndrome (COV-AID): a factorial, randomised, controlled trial.
    Declercq J; Van Damme KFA; De Leeuw E; Maes B; Bosteels C; Tavernier SJ; De Buyser S; Colman R; Hites M; Verschelden G; Fivez T; Moerman F; Demedts IK; Dauby N; De Schryver N; Govaerts E; Vandecasteele SJ; Van Laethem J; Anguille S; van der Hilst J; Misset B; Slabbynck H; Wittebole X; Liénart F; Legrand C; Buyse M; Stevens D; Bauters F; Seys LJM; Aegerter H; Smole U; Bosteels V; Hoste L; Naesens L; Haerynck F; Vandekerckhove L; Depuydt P; van Braeckel E; Rottey S; Peene I; Van Der Straeten C; Hulstaert F; Lambrecht BN
    Lancet Respir Med; 2021 Dec; 9(12):1427-1438. PubMed ID: 34756178
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hydroxychloroquine in the treatment of adult patients with Covid-19 infection in a primary care setting (LIBERTY): A structured summary of a study protocol for a randomised controlled trial.
    Vainio PJ; Hietasalo P; Koivisto AL; Kääriäinen S; Turunen J; Virtala M; Vuorinen J; Scheinin M
    Trials; 2021 Jan; 22(1):44. PubMed ID: 33430933
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared with Best Supportive Care in Patients with COVID-19 Severe Pneumonia, Acute Lung Injury, or Acute Respiratory Distress Syndrome: A structured summary of a study protocol for a randomised controlled trial.
    Smith K; Pace A; Ortiz S; Kazani S; Rottinghaus S
    Trials; 2020 Jul; 21(1):639. PubMed ID: 32660611
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Imatinib in patients with severe COVID-19: a randomised, double-blind, placebo-controlled, clinical trial.
    Aman J; Duijvelaar E; Botros L; Kianzad A; Schippers JR; Smeele PJ; Azhang S; Bartelink IH; Bayoumy AA; Bet PM; Boersma W; Bonta PI; Boomars KAT; Bos LDJ; van Bragt JJMH; Braunstahl GJ; Celant LR; Eger KAB; Geelhoed JJM; van Glabbeek YLE; Grotjohan HP; Hagens LA; Happe CM; Hazes BD; Heunks LMA; van den Heuvel M; Hoefsloot W; Hoek RJA; Hoekstra R; Hofstee HMA; Juffermans NP; Kemper EM; Kos R; Kunst PWA; Lammers A; van der Lee I; van der Lee EL; Maitland-van der Zee AH; Mau Asam PFM; Mieras A; Muller M; Neefjes ECW; Nossent EJ; Oswald LMA; Overbeek MJ; Pamplona CC; Paternotte N; Pronk N; de Raaf MA; van Raaij BFM; Reijrink M; Schultz MJ; Serpa Neto A; Slob EMA; Smeenk FWJM; Smit MR; Smits AJ; Stalenhoef JE; Tuinman PR; Vanhove ALEM; Wessels JN; van Wezenbeek JCC; Vonk Noordegraaf A; de Man FS; Bogaard HJ
    Lancet Respir Med; 2021 Sep; 9(9):957-968. PubMed ID: 34147142
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Responses to a Neutralizing Monoclonal Antibody for Hospitalized Patients With COVID-19 According to Baseline Antibody and Antigen Levels : A Randomized Controlled Trial.
    ; Lundgren JD; Grund B; Barkauskas CE; Holland TL; Gottlieb RL; Sandkovsky U; Brown SM; Knowlton KU; Self WH; Files DC; Jain MK; Benfield T; Bowdish ME; Leshnower BG; Baker JV; Jensen JU; Gardner EM; Ginde AA; Harris ES; Johansen IS; Markowitz N; Matthay MA; Østergaard L; Chang CC; Goodman AL; Chang W; Dewar RL; Gerry NP; Higgs ES; Highbarger H; Murray DD; Murray TA; Natarajan V; Paredes R; Parmar MKB; Phillips AN; Reilly C; Rupert AW; Sharma S; Shaw-Saliba K; Sherman BT; Teitelbaum M; Wentworth D; Cao H; Klekotka P; Babiker AG; Davey VJ; Gelijns AC; Kan VL; Polizzotto MN; Thompson BT; Lane HC; Neaton JD
    Ann Intern Med; 2022 Feb; 175(2):234-243. PubMed ID: 34928698
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and Safety of Pacritinib vs Placebo for Patients With Severe COVID-19: A Phase 2 Randomized Clinical Trial.
    Cafardi J; Miller C; Terebelo H; Tewell C; Benzaquen S; Park D; Egan P; Lebovic D; Pettit K; Whitman E; Tremblay D; Feld J; Buckley S; Roman-Torres K; Smith J; Craig A; Mascarenhas J
    JAMA Netw Open; 2022 Dec; 5(12):e2242918. PubMed ID: 36469321
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of previous exposure to SARS-CoV-2 and of S-Trimer (SCB-2019) COVID-19 vaccination on the risk of reinfection: a randomised, double-blinded, placebo-controlled, phase 2 and 3 trial.
    Smolenov I; Han HH; Li P; Baccarini C; Verhoeven C; Rockhold F; Clemens SAC; Ambrosino D; Richmond P; Siber G; Liang J; Clemens R;
    Lancet Infect Dis; 2022 Jul; 22(7):990-1001. PubMed ID: 35447085
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey.
    Tanriover MD; Doğanay HL; Akova M; Güner HR; Azap A; Akhan S; Köse Ş; Erdinç FŞ; Akalın EH; Tabak ÖF; Pullukçu H; Batum Ö; Şimşek Yavuz S; Turhan Ö; Yıldırmak MT; Köksal İ; Taşova Y; Korten V; Yılmaz G; Çelen MK; Altın S; Çelik İ; Bayındır Y; Karaoğlan İ; Yılmaz A; Özkul A; Gür H; Unal S;
    Lancet; 2021 Jul; 398(10296):213-222. PubMed ID: 34246358
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of the efficacy and safety of intravenous remdesivir in adult patients with severe COVID-19: study protocol for a phase 3 randomized, double-blind, placebo-controlled, multicentre trial.
    Wang Y; Zhou F; Zhang D; Zhao J; Du R; Hu Y; Cheng Z; Gao L; Jin Y; Luo G; Fu S; Lu Q; Du G; Wang K; Lu Y; Fan G; Zhang Y; Liu Y; Ruan S; Liu W; Jaki T; Hayden FG; Horby PW; Cao B; Wang C
    Trials; 2020 May; 21(1):422. PubMed ID: 32448345
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ibrutinib for Hospitalized Adults With Severe Coronavirus Disease 2019 Infection: Results of the Randomized, Double-Blind, Placebo-Controlled iNSPIRE Study.
    Coutre SE; Barnett C; Osiyemi O; Hoda D; Ramgopal M; Fort AC; Qaqish R; Hu Y; Ninomoto J; Alami NN; Styles L; Treon SP
    Open Forum Infect Dis; 2022 May; 9(5):ofac104. PubMed ID: 35493119
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Interferon Inhibition for Lupus with Anifrolumab: Critical Appraisal of the Evidence Leading to FDA Approval.
    Loncharich MF; Anderson CW
    ACR Open Rheumatol; 2022 Jun; 4(6):486-491. PubMed ID: 35157371
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.